PRS

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Retrieved on: 
星期日, 十月 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, Appetite, DXD, PRS, PD-L1, Constipation, AstraZeneca, PD, Vomiting, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, CRS, HIV disease progression rates, TNBC, ADC, Dor, TSE, Breast cancer, ORR, ILD, Arm, Patient, Breast, Barts and The London School of Medicine and Dentistry, Fatigue, Medical imaging, Pharmaceutical industry, Daiichi Sankyo, Durvalumab

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • “These results for datopotamab deruxtecan plus durvalumab in the first-line triple negative breast cancer setting are highly encouraging, particularly the 79% objective response rate,” said Peter Schmid, MD, Barts Cancer Institute, London, United Kingdom, and investigator in the trial.
  • “Disease progression after initial treatment is a reality for patients with triple negative breast cancer, underscoring the need for more durable treatment options,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo.
  • As of the February 2, 2023 data cut-off, 29 patients (47%) remained on study treatment.

Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

Retrieved on: 
星期一, 十月 23, 2023
TKI, Bone marrow, PRS, NSCLC, Notifiable disease, Mini, Aes, ESMO, TP53, QW, Hepatitis, Congress, PFS, European Society for Medical Oncology, CHB, Pharmacokinetics, Disease, Oncology, ORR, Safety, Cancer, Apoptosis, Patient, Prognosis, Cohort, EGFR, Pharmaceutical industry

The clinical data presented at the ESMO Congress this year demonstrated promising therapeutic utility of pelcitoclax combined with osimertinib in patients with EGFR-mutant NSCLC.

Key Points: 
  • The clinical data presented at the ESMO Congress this year demonstrated promising therapeutic utility of pelcitoclax combined with osimertinib in patients with EGFR-mutant NSCLC.
  • Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, "Currently, there are many challenges in the treatment of NSCLC.
  • At the ESMO 2023, we presented the latest clinical data that continued to suggest encouraging therapeutic potential of pelcitoclax combined with osimertinib in EGFR-TKI-naïve patients with TP53- and EGFR-mutant NSCLC.
  • In earlier studies, pelcitoclax combined with osimertinib demonstrated clinical potential for the treatment of patients with EGFR-mutant advanced NSCLC resistant to EGFR-TKIs.

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Retrieved on: 
星期六, 十月 14, 2023
Diamond, Cancer, Neoplasm, RAF, KRAS, Memorial Sloan Kettering Cancer Center, Immortalised cell line, NSCLC, GBM, Allele, AACR, BRAF, ORR, Aes, DNA, EGFR, Mutation, Survival, Black Diamond, M26 Modular Accessory Shotgun System, FDA, NRAS, Therapy, RECIST, PRS, Associate, Mouse, Patient, TKI, Circulating tumor DNA, Infrared spectroscopy correlation table, MAPK, CNS, Conference, Pharmaceutical industry, Dietary supplement, Vaccine, Medical imaging, Glioblastoma

CAMBRIDGE, Mass. and NEW YORK, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today presented results demonstrating encouraging response durability of BDTX-1535 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). BDTX-1535, a fourth-generation, brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, is under investigation in a Phase 1 clinical trial for patients with NSCLC or glioblastoma multiforme (GBM). The NSCLC results were disclosed in a poster presentation on October 14, 2023 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Key Points: 
  • BDTX-1535, a fourth-generation, brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, is under investigation in a Phase 1 clinical trial for patients with NSCLC or glioblastoma multiforme (GBM).
  • Data shared at the 2023 AACR-NCI-EORTC conference reflects 27 patients with advanced/metastatic NSCLC who received a range of doses spanning 25mg to 400mg once daily.
  • “These dose escalation results underscore that the well-tolerated and durable clinical activity of BDTX-1535 could have important implications for patients with EGFR mutant NSCLC,” said Sergey Yurasov, M.D., Ph.D., Chief Medical Officer of Black Diamond Therapeutics.
  • Black Diamond initiated a Phase 1 clinical trial for BDTX-4933 with emphasis on KRAS mutant NSCLC in the second quarter of 2023.

Enjoy 20% Off PRS SE Series Electric Guitars This Holiday Season

Retrieved on: 
星期四, 十月 12, 2023
Music, PRS Guitars, SE, PRS, ALL, Sale, MD

Stevensville, MD, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Just in time for the holiday season, PRS Guitars is hosting a PRS SE Series Holiday Sales Event.

Key Points: 
  • Stevensville, MD, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Just in time for the holiday season, PRS Guitars is hosting a PRS SE Series Holiday Sales Event.
  • From October 12 – December 31, 2023, enjoy 20% off ALL PRS SE Series electric guitars (PRS SE DGT excluded, remaining solid body, semi-hollow, hollowbody, and bass guitars are included).
  • Offering an array of guitar models and styles, the PRS SE Series complements PRS Guitars’ Maryland-made PRS line by offering highly approachable and more affordable electric, acoustic, and bass guitars.
  • We are hopeful that this sales event will get the SE Series into more hands than ever this holiday season so more people can experience the joy of making music,” said Jack Higginbotham, PRS Guitars COO.

Qwoted Launches Free Networking Tools for PR Industry

Retrieved on: 
星期三, 十月 4, 2023
Apps, Applications, Technology, Public Relations, Investor Relations, Marketing, Advertising, Communications, Internet, Social Media, Blogging, Now (newspaper), Communication, Integral, PRS, PR, Qwote, Media

Qwoted has launched a new feature creating the world’s first social collaborative network for the PR industry.

Key Points: 
  • Qwoted has launched a new feature creating the world’s first social collaborative network for the PR industry.
  • With PR-to-PR messaging, Qwoted users have the ability to connect with colleagues and industry peers to share insights, best practices, and job opportunities on the world’s largest PR network.
  • The Qwoted network has grown to over 100,000 members of the PR community.
  • "It's exciting to see Qwoted continue to drive innovation in the PR industry," said J.J. Colao, Founder of Haymaker Group.

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)

Retrieved on: 
星期四, 九月 28, 2023
Columbia University, PDAC, Pancreatic cancer, AACR, CXCR4, PRS, Hope, BioLineRx, Immunotherapy, Doctor of Philosophy, ASCO, TEL, MD, Patient, Pancreas, Columbia University Irving Medical Center, TASE, Cancer, Annual general meeting, American Society of Clinical Oncology, Liver, Rare, PD-1, American Association for Cancer Research, Gemcitabine, Partial-response maximum-likelihood, Society, Conference, Pharmaceutical industry

TEL AVIV, Israel, Sept. 28, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced encouraging data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).

Key Points: 
  • The data were published in an online abstract as part of the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023.
  • The pilot phase of the Phase 2 study enrolled 11 patients with metastatic pancreatic cancer.
  • A poster of the amended clinical trial design was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6 in Chicago, Illinois (see abstract ).
  • Most pancreatic cancer is incurable and unfortunately newer immunotherapy approaches, while beneficial against other solid tumor types, have had limited efficacy in pancreatic cancer due to immunosuppressive pathways.

LinearB Releases Expanded 2023 Software Engineering Benchmarks Report with Key Resource Investment Metrics

Retrieved on: 
星期二, 九月 26, 2023
Cloud, PRS, Engineering, Culture, Google Cloud Platform, DORA, Research, Organization, Acceleration, Annual report, Geographic Locator Codes, Risk management, Airline

LOS ANGELES, Sept. 26, 2023 /PRNewswire/ -- Today, LinearB released its updated 2023 Engineering Benchmarks Report, offering a critical look into the key resource and investment metrics distinguishing elite engineering organizations of all sizes. This comprehensive report provides updated insights and data from a study of over 2,000 development teams across 64 countries and more than 3.6 million pull requests (PRs).

Key Points: 
  • LOS ANGELES, Sept. 26, 2023 /PRNewswire/ -- Today, LinearB released its updated 2023 Engineering Benchmarks Report , offering a critical look into the key resource and investment metrics distinguishing elite engineering organizations of all sizes.
  • This ongoing research inspired LinearB's 2023 Software Engineering Benchmarks Report, empowering engineering teams to benchmark their performance against industry standards, aiding in operational efficiency and resource alignment.
  • "Our 2023 Software Engineering Benchmarks Report is a valuable tool for engineering teams seeking to elevate their performance," said Ori Keren, CEO and co-founder at LinearB.
  • The 2023 Engineering Benchmarks Report introduces the ability to segment benchmarks across different organization sizes.

Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring

Retrieved on: 
星期一, 九月 18, 2023
Perk, NRAS, Workforce, FGFR, DNA, Pancreatic cancer, DUSP6, PRS, Class II, Class, DCR, Clinical trial, DC, DL 2, Trae tha Truth, First grade, MEK inhibitor, BRAF, Research, Itch, MEK, RNA, Lung cancer, Completeness, Binimetinib, Rash, ORR, Vomiting, Investment, Patient, SAN, Melanoma, ERK, Weakness, Nausea, ALT, Neoplasm, CDK4, FDA, FGFR2, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, SD, KNTE, Food, PR, Safety, Fatigue, RAF, Pharmaceutical industry, Cryptocurrency, Medical imaging, Vaccine

(Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.

Key Points: 
  • (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.
  • Additionally, Kinnate will pause development of KIN-7136 and explore strategic alternatives for exarafenib monotherapy and KIN-3248, as part of the reprioritization plan.
  • We believe that reprioritizing our programs is the most effective approach to unlock the full promise of our innovative therapies.”
    Farzan added, “The reprioritization plan unfortunately impacts our workforce.
  • Kinnate will implement a corporate restructuring by reducing the Company’s workforce by approximately 70%.

Presto Foundation Announces Contributions by IBM and Uber that Reinforce Commitment to the Presto Open Source Community

Retrieved on: 
星期三, 九月 20, 2023
Software, Mobile, Wireless, Networks, Internet, Professional Services, Philanthropy, Data Management, Technology, Security, Data Analytics, Foundation, Telecommunications, IBM, PRS, SQL, Confluence, Meta, HBO, Redis, Uber, Linux Foundation, Architecture, AWS Glue, Visa, Community, Acquisition, Linux, Engineering, S3, Digital Extremes, AWS, AWS S3, Forging, Tencent, News broadcasting, Amazon

The Presto Foundation announced two significant new contributions to Presto, the open source SQL query engine for data analytics and the open data lakehouse.

Key Points: 
  • The Presto Foundation announced two significant new contributions to Presto, the open source SQL query engine for data analytics and the open data lakehouse.
  • IBM is donating its AWS Lake Formation integration for Presto, and Uber is donating its Redis-based historical statistics provider for Presto.
  • The donation of an AWS Lake Formation integration to the open source Presto community by IBM, which recently joined the Presto Foundation through its acquisition of Ahana, automates the configuration of Presto and AWS Lake Formation.
  • In addition to the two contributions from IBM and Uber, the Presto community is also celebrating additional recent updates.

Kennedy Wilson Announces Retirement of Mary Ricks as President and Transition Plan

Retrieved on: 
星期四, 九月 14, 2023
Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Finance, Construction & Property, REIT, Kennedy Wilson, Executive, Partnership, PRS, KWW, Strategic planning, Diversity, KW, Inclusion, Woman, NYSE, Management, Renewable energy, EU

Global real estate investment company Kennedy Wilson (NYSE: KW) today announced that after 33 years of dedicated service, Mary Ricks has decided to retire as President of Kennedy Wilson and as Director on the company’s Board.

Key Points: 
  • Global real estate investment company Kennedy Wilson (NYSE: KW) today announced that after 33 years of dedicated service, Mary Ricks has decided to retire as President of Kennedy Wilson and as Director on the company’s Board.
  • Mary will serve as a consultant to Kennedy Wilson to aid in the transition.
  • I am very grateful to Bill for the opportunity and for our friendship and partnership over these many years.”
    Concurrently, former Executive Vice President Matt Windisch was promoted to President of Kennedy Wilson.
  • Former Head of UK Mike Pegler, who has been with Kennedy Wilson for nearly a decade, will also assume a new role as President of Kennedy Wilson Europe.